580 results on '"Secondary cancer"'
Search Results
2. A New Sarcoma Shortly after Treatment for High-Grade Glioma with Adjuvant Chemoradiation: A Case Report
- Author
-
Abdossalam M. Madkhali, Hasah F. Alaluan, Mohammed H. Alnajeim, Eyad F. Al Saeed, Abdulrazag M. Ajlan, Ahmed Abdelwarith, Ali Abduh, Saleh Albanyan, Ashwag Alqurashi, and Hisham Alkhalidi
- Subjects
sarcoma ,high-grade glioma ,glioblastoma ,radiation ,complication ,secondary cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Introduction: High-grade gliomas are central nervous system tumors conventionally treated with surgery followed by adjuvant chemoradiotherapy. Secondary cancer due to radiation therapy is a rare yet established phenomenon that typically occurs years after radiation therapy. Case Presentation: In this case, we discuss an early presentation of a second cancer adjacent to the radiation field. This case report is of a 52-year-old male who developed a new scalp sarcoma at the site of primary surgery 8 months after radiation therapy. Genetic testing revealed a heterozygous missense variant in the NF1 gene, a variant of uncertain significance. The report highlights that this case does not conform to the expected criteria for postradiation sarcoma in terms of timing. Conclusion: Secondary cancers may arise earlier than expected, even in phenotypically normal patients, as they may have unmanifested variants of relevant mutations. The question of pre-radiotherapy screening for radiosensitivity syndromes and diseases requires further study, as current data are limited and do not provide enough insight into the significance of different genetic variants.
- Published
- 2024
- Full Text
- View/download PDF
3. Unraveling trajectories from aplastic anemia to hematologic malignancies: genetic and molecular insights.
- Author
-
Namsoo Kim, Yu Jeong Choi, Seung-Tae Lee, Jong Rak Choi, Chuhl Joo Lyu, Saeam Shin, and June-Won Cheong
- Subjects
HEMATOLOGIC malignancies ,APLASTIC anemia ,CHRONIC leukemia ,ACUTE myeloid leukemia ,HEMATOPOIETIC stem cells ,MYELODYSPLASTIC syndromes - Abstract
Background: Aplastic anemia (AA), characterized by hematopoietic stem cell deficiency, can evolve into different hematologic malignancies. Our understanding of the genetic basis and mechanisms of this progression remains limited. Methods: We retrospectively studied 9 acquired AA patients who later developed hematologic malignancies. Data encompassed clinical, laboratory, karyotype, and next-generation sequencing (NGS) information. We explored chromosomal alterations and mutation profiles to uncover genetic changes underlying the transition. Results: Nine AA patients developed myelodysplastic syndrome (seven patients), acute myeloid leukemia (one patient), or chronic myelomonocytic leukemia (one patient). Among eight patients with karyotype results at secondary malignancy diagnosis, monosomy 7 was detected in three. Trisomy 1, der(1;7), del(6q), trisomy 8, and del(12p) were detected in one patient each. Among three patients with NGS results at secondary malignancy diagnosis, KMT2C mutation was detected in two patients. Acquisition of a PTPN11 mutation was observed in one patient who underwent follow-up NGS testing during progression from chronic myelomonocytic leukemia to acute myeloid leukemia. Conclusion: This study highlights the genetic dynamics in the progression from AA to hematologic malignancy. Monosomy 7's prevalence and the occurrence of PTPN11 mutations suggest predictive and prognostic significance. Clonal evolution underscores the complexity of disease progression. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Incidence of Secondary Cancers After Neoadjuvant Therapy for Locally Advanced Rectal Cancer.
- Author
-
Raje, Praachi, Sonal, Swati, Boudreau, Chloe, Kunitake, Hiroko, Goldstone, Robert N., Bordeianou, Liliana G., Cauley, Christy E., Francone, Todd D., Ricciardi, Rocco, Lee, Grace C., and Berger, David L.
- Subjects
- *
RECTAL cancer , *NEOADJUVANT chemotherapy , *GENETIC mutation , *DISEASE risk factors , *ODDS ratio , *CANCER patients - Abstract
Whether neoadjuvant chemoradiation for locally advanced rectal cancer (LARC) induces secondary cancers is controversial. This retrospective cohort study describes the incidence of secondary cancers in LARC patients. We compared 364 LARC patients who received conventional (50.4 Gy) or short course neoadjuvant radiation (25 Gy x 5 fractions) followed by resection to 142 patients with surgically resected rectal cancer who did not receive radiation at a single institution from 2004 to 2018. Secondary cancer was defined as any nonmetastatic noncolorectal malignancy diagnosed via biopsy or definitive imaging criteria at least 6 mo after completion of neoadjuvant therapy or after resection in the comparison group. Among the neoadjuvant radiation group (364 patients, 40% female, age 61 ± 13 y), 32 patients developed 34 (9.3%) secondary cancers. Three cases involved a pelvic organ. Among the comparison group (142 patients, 39% female, age 64 ± 15 y), 15 patients (10.6%) developed a secondary cancer. Five cases involved pelvic organs. Secondary cancer incidence did not differ between groups. Latency period to secondary cancer diagnosis was 6.7 ± 4.3 y. Patients who received radiation underwent longer median follow-up (6.8 versus 4.5 y, P < 0.01) and were significantly less likely to develop a pelvic organ cancer (odds ratio 0.18; 95% confidence interval, 0.04-0.83; P = 0.02). No genetic mutations or cancer syndromes were identified among patients with secondary cancers. Neoadjuvant chemoradiation is not associated with increased secondary cancer risk in LARC patients and may have a local protective effect on pelvic organs, especially prostate. Ongoing follow-up is critical to continue risk assessment. • Rectal radiation does not increase secondary cancer risk over a 7-y follow-up. • Secondary pelvic cancers, that is prostate, are less likely after rectal radiation. • Rectal radiation may have a local protective effect. • Ongoing follow-up is key to understanding long-term radiation risks. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Exploring tonsillar cancer associations in patients with base of tongue cancer: insights from a single-center study
- Author
-
Udholm, Sebastian, Sannino-Greve, Nina B., and Klug, Tejs Ehlers
- Published
- 2024
- Full Text
- View/download PDF
6. Secondary cancer risk estimation following prostate cancer radiotherapy through gEUD concept and NCRP-116 recommendations.
- Author
-
Zoljalali Moghaddam, S. H., Eyvazzadeh, N., Rezakhaniha, B., Bagheri, H., Jalaei-Kho, H., Baghani, H. R., Mahdavi, S. R., and Ardalan, M. Afshar
- Subjects
- *
CANCER radiotherapy , *DISEASE risk factors , *PROSTATE cancer , *PROSTATE cancer patients , *ABSORBED dose - Abstract
Background: Radiotherapy is one of the practical modalities in prostate cancer treatment, but there is a risk of developing secondary cancers caused by unintended radiation inside the non-target organs. The current study aimed to evaluate the risk of secondary cancer development in organs at risk (the bladder and rectum) following prostate cancer radiotherapy. Materials and Methods: A group of 39 patients with prostate cancer who were treated with 3-dimensional conformal radiotherapy (3DCRT) were enrolled. A dose-volume histogram (DVH) corresponding to each patient was utilized to estimate the absorbed dose for the rectum and bladder and to calculate their respective generalized equivalent uniform dose (gEUD). Finally, the risk of secondary malignancies was estimated by employing the gEUD values and recommended risk factors by the National Council on Radiation Protection and Measurements (NCRP) 116. Results: The gEUD values for the rectum and bladder ranged from 50-75 and 25-80, respectively. The mean gEUD values for the rectum and bladder were correspondingly equal to 60.97 Sv and 53.74 Sv, respectively. The mean secondary cancer risk (SCR) value for the rectum was 30.4%, while about 16.1% was estimated for the bladder. The estimated SCR in the rectum was 1.88 times higher than in the bladder. Conclusions: The rectum is more exposed to radiation and is endangered by the development of secondary cancer following prostate cancer radiotherapy. Nevertheless, the probability of cancer incidence in the bladder was also considerable. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. A New Sarcoma Shortly after Treatment for High-Grade Glioma with Adjuvant Chemoradiation: A Case Report.
- Author
-
Madkhali, Abdossalam M., Alaluan, Hasah F., Alnajeim, Mohammed H., Al Saeed, Eyad F., Ajlan, Abdulrazag M., Abdelwarith, Ahmed, Abduh, Ali, Albanyan, Saleh, Alqurashi, Ashwag, and Alkhalidi, Hisham
- Subjects
- *
SARCOMA , *GLIOMAS , *CHEMORADIOTHERAPY , *GENETIC variation , *CANCER radiotherapy , *BRAIN tumors ,CENTRAL nervous system tumors - Abstract
Introduction: High-grade gliomas are central nervous system tumors conventionally treated with surgery followed by adjuvant chemoradiotherapy. Secondary cancer due to radiation therapy is a rare yet established phenomenon that typically occurs years after radiation therapy. Case Presentation: In this case, we discuss an early presentation of a second cancer adjacent to the radiation field. This case report is of a 52-year-old male who developed a new scalp sarcoma at the site of primary surgery 8 months after radiation therapy. Genetic testing revealed a heterozygous missense variant in the NF1 gene, a variant of uncertain significance. The report highlights that this case does not conform to the expected criteria for postradiation sarcoma in terms of timing. Conclusion: Secondary cancers may arise earlier than expected, even in phenotypically normal patients, as they may have unmanifested variants of relevant mutations. The question of pre-radiotherapy screening for radiosensitivity syndromes and diseases requires further study, as current data are limited and do not provide enough insight into the significance of different genetic variants. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Dose comparison of robustly optimized intensity modulated proton therapy (IMPT) vs IMRT and VMAT photon plans for testicular seminoma.
- Author
-
Rønde, Heidi S., Kronborg, Camilla, Høyer, Morten, Hansen, Jolanta, Bak, Malene Eppler, Agergaard, Søren Nielsen, Als, Anne Birgitte, Agerbæk, Mads, Lauritsen, Jakob, Petersen, Peter Meidahl, Dysager, Lars, and Kallehauge, Jesper F.
- Subjects
- *
STATISTICS , *MANN Whitney U Test , *TESTIS tumors , *PROTON therapy , *RADIATION doses , *SECONDARY primary cancer , *DESCRIPTIVE statistics , *RADIOTHERAPY , *COMPUTED tomography , *DATA analysis , *DATA analysis software , *SEMINOMA , *DISEASE risk factors - Abstract
Background: Patients with stage II seminoma have traditionally been treated with photons to the retroperitoneal and iliac space, which leads to a substantial dose bath to abdominal and pelvic organs at risk (OAR). As these patients are young and with excellent prognosis, reducing dose to OAR and thereby the risk of secondary cancer is of utmost importance. We compared IMPT to opposing IMRT fields and VMAT, assessing dose to OAR and both overall and organ-specific secondary cancer risk. Material and methods: A comparative treatment planning study was conducted on planning CTscans from ten patients with stage II seminoma, treated with photons to a 'dog-leg' field with doses ranging from 20 to 25Gy and a 10Gy sequential boost to the metastatic lymph node(s). Photon plans were either 3-4 field IMRT (Eclipse) or 1-2 arc VMAT (Pinnacle). Proton plans used robust (5mm; 3.5%) IMPT (Eclipse), multi field optimization with 3 posterior fields supplemented by 2 anterior fields at the level of the iliac vessels. Thirty plans were generated. Mean doses to OARs were compared for IMRT vs IMPT and VMAT vs IMPT. The risk of secondary cancer was calculated according to the model described by Schneider, using excess absolute risk (EAR, per 10,000 persons per year) for body outline, stomach, duodenum, pancreas, bowel, bladder and spinal cord. Results: Mean doses to all OARs were significantly lower with IMPT except similar kidney (IMRT) and spinal cord (VMAT) doses. The relative EAR for body outline was 0.59 for IMPT/IMRT (p<.05) and 0.33 for IMPT/VMAT (p<.05). Organ specific secondary cancer risk was also lower for IMPT except for pancreas and duodenum. Conclusion: Proton therapy reduced radiation dose to OAR compared to both IMRT and VMAT plans, and potentially reduce the risk of secondary cancer both overall and for most OAR. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Hybrid planning techniques for early-stage left-sided breast cancer: dose distribution analysis and estimation of projected secondary cancer-relative risk.
- Author
-
Racka, Iga, Majewska, Karolina, Winiecki, Janusz, and Kiluk, Karolina
- Subjects
- *
THREE-dimensional imaging , *ONE-way analysis of variance , *RETROSPECTIVE studies , *RISK assessment , *DOSE-response relationship (Radiation) , *PEARSON correlation (Statistics) , *RADIATION doses , *DESCRIPTIVE statistics , *RADIOTHERAPY , *RESPIRATION , *BREAST tumors , *BREATH holding , *RADIATION dosimetry ,PLANNING techniques - Abstract
The purpose of this study was to evaluate three techniques of irradiation of left-sided breast cancer patients, three-dimensional conformal radiotherapy (3D-CRT), hybrid Intensity-Modulated Radiotherapy (h-IMRT), and hybrid Volumetric-Modulated Arc Therapy (h-VMAT, h-ARC), in terms of dose distribution in the planning target volume (PTV) and organs at risk (OARs). The second aim was to estimate the projected relative risk of radiation-induced secondary cancers for hybrid techniques. Three treatment plans were prepared in 3D-CRT, h-IMRT, and h-VMAT techniques for each of the 40 patients, who underwent CT simulation in deep inspiration breath-hold (DIBH). For hybrid techniques, plans were created by combining 3D-CRT and dynamic fields with an 80%/20% dose ratio for 3D-CRT and IMRT or VMAT. Cumulative dose–volume histograms were used to compare dose distributions within the PTV and OARs (heart, left anterior descending coronary artery [LAD], left and right lung [LL, RL], right breast [RB]). Projected risk ratios for secondary cancers were estimated relative to 3D-CRT using the organ equivalent dose (OED) concept for the Schneider's linear exponential, plateau, and full mechanistic dose–response model. All plans fulfilled the PTV criterium: V95%≥95%. Compared to 3D-CRT, both hybrid techniques showed significantly better target coverage (PTV: V95%>98%, p < 0.001), and the best conformality was achieved by h-ARC plans (CI: 1.18 ± 0.09, p < 0.001). Compared to 3D-CRT and h-ARC, h-IMRT increased the average sum of monitor units (MU) over 129.9% (p < 0.001). H-ARC increased the mean dose of contralateral organs and the LL V5Gy parameter (p < 0.001). Both hybrid techniques significantly reduced the Dmax of the heart by 5 Gy. Compared to h-IMRT, h-ARC increased secondary cancer projected relative risk ratios for LL, RL, and RB by 18, 152, and 81%, respectively. The results confirmed that both hybrid techniques provide better target quality and OARs sparing than 3D-CRT. Hybrid VMAT delivers less MU compared to hybrid IMRT but may increase the risk of radiation-induced secondary malignancies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. A pilot randomized controlled trial of an online intervention for Hodgkin lymphoma survivors to increase knowledge about late effects and recommended screening
- Author
-
Rick, Tara J., Sagaram, Smitha, Jewett, Patricia I., Lee, Hee Yun, Sadak, Karim T., Turcotte, Lucie M., Vogel, Rachel I., and Blaes, Anne
- Published
- 2024
- Full Text
- View/download PDF
11. Incidence and risk factors for second malignancies among patients with myeloproliferative neoplasms
- Author
-
Yuhui Zhang, Yingdi Han, Guangshuai Teng, Chenxiao Du, Shan Gao, Weiping Yuan, Lei Zhang, and Jie Bai
- Subjects
clinical characteristics ,myeloproliferative neoplasms ,risk factors ,secondary cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Objective The clinical characteristics and survival of patients with myeloproliferative neoplasms (MPNs) with secondary cancer were analyzed to explore the possible risk factors for secondary cancer in MPN patients. Methods The clinical characteristics of 1060 Chinese patients with MPN were retrospectively analyzed. The Kaplan–Meier method was used to analyze the survival. The Cox multivariate regression model was used to analyze the risk factors for developing secondary cancer in patients with MPNs. Results The 1060 patients with MPN had a median follow‐up of 10 years (range 1–50) and a median age of 55 years (range 21–86), and 497 (45.2%) were male. The proportion of PV, ET, and PMF was 52.2%, 33.5%, and 14.3%, respectively. About 28.1% (298/1060) of 1060 MPN patients died. The median survival times of the PV, ET, and PMF groups were 20, 24, and 12 years, respectively (p
- Published
- 2023
- Full Text
- View/download PDF
12. Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial.
- Author
-
Phillips, Tycel, Migliaccio-Walle, Kristen, Yu, Kristina S., Bloudek, Brian, Liu, Nicholas, Fanale, Michelle, and Burke, John M.
- Subjects
- *
HODGKIN'S disease , *OVERALL survival , *SIMULATION methods & models , *STEM cell transplantation , *ONCOLOGY - Abstract
The six-year ECHELON-1 update showed a survival advantage for frontline (1 L) A + AVD (brentuximab vedotin, doxorubicin, vinblastine, dacarbazine) vs ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for stage III/IV classic Hodgkin lymphoma (cHL). As clinical trials have limited ability to track patients for extended periods, we developed an oncology simulation model using ECHELON-1 data to estimate population-based cHL outcomes in the US over 10 years (through 2031). The model included a scenario without (64.5% ABVD, 35.5% PET-adapted ABVD utilization) and scenarios with 1 L A + AVD (27%–80%k utilization). At 27%–80% A + AVD utilization, the model estimated 13.6%–31.7% fewer deaths, 2.4%–6.3% more patients ≥5 years progression free, 9.4%–24.4% fewer stem cell transplants (SCTs), and 7.8%–22.5% fewer second cancers over 10 years. These results suggest that the improved outcomes observed in the ECHELON-1 update with A + AVD vs ABVD may translate to more patients alive and fewer with primary relapsed/refractory cHL, SCTs, and second cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. Problems Faced by Mothers of whose Children have Survived Cancer that Appeared During the Life Stages of the Children and the Process and Guidance for Self-Care.
- Author
-
Kyoko Shimoyama and Masaru Nakamura
- Subjects
HUMAN growth ,CHILD care ,ATTITUDES of mothers ,CHILD development ,PSYCHOLOGY of mothers ,CONVALESCENCE ,RESEARCH methodology ,GROUNDED theory ,INTERVIEWING ,CANCER patients ,TUMORS in children ,QUALITATIVE research ,AGE factors in disease ,RESEARCH funding ,HEALTH self-care ,DISCHARGE planning ,DISEASE complications ,CHILDREN - Abstract
Background: Childhood cancers affect 2,000-2,500 individuals per year in Japan, with onset at infancy. In Japan, there are ~50,000 childhood cancer survivors, and following recovery, the mother supports the child at home. Aim: To elucidate how mothers confront problems following the discharge of childhood cancer survivors and the provision of guidance to the child regarding self-care. Methodology: After creating an interview guide coinciding with the study objectives, semi-structured interviews of five mothers of childhood cancer survivors were conducted. The data obtained was analyzed using the modified grounded theory approach. Results: The challenges faced by mothers of childhood cancer survivors who underwent surgery as children and the self-care guidance process comprised 5 core categories and nine categories from 34 concepts. The core categories included "formation of beliefs to confront the disease," "promotion of understanding suitable to the child's age at onset," "individual actions against the lack of information," "preparation of the environment by oneself when the child needs to be monitored," and "reflection and acknowledgment of the process to date." Conclusions: The mothers of childhood cancer survivors with onset at infancy preferred for the child to understand their disease; however, the mothers experienced difficulty in explaining the disease owing to a lack of knowledge. To enhance their knowledge to facilitate the child's self-care, mothers joined patient groups to gather information. Furthermore, following discharge, it was difficult for parents and their children to establish relationships with medical staff and no avenue was available for consultation in case of any concerns. [ABSTRACT FROM AUTHOR]
- Published
- 2023
14. Primary Ewing's sarcoma/primitive neuroectodermal tumor of the kidney and its clinical features
- Author
-
Shiori Saikawa, Minekatsu Taga, Yasushi Matsuda, Koji Suzuki, Aina Yamaguchi, Mana Fukushima, Yoshiaki Imamura, Hideaki Ito, and Osamu Yokoyama
- Subjects
Ewing sarcoma ,primary renal ESFT ,secondary cancer ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Introduction Ewing sarcoma family tumor is a malignant tumor that is primarily of bone origin; it rarely occurs in the kidney. Case presentation A 22‐year‐old woman presented with hematuria. Computed tomography revealed a 6 × 6‐cm mass in the lower pole of the right kidney with invasion into the right renal vein. A right laparoscopic radical nephrectomy was performed. The tumor was completely encapsulated. Based on the small‐round‐cell histology, diffusely CD99‐positive tumor cells, and EWS (ex7)–FLi1 (ex6) fusion gene break point transcript, we diagnosed Ewing sarcoma/primitive neuroectodermal tumor of the kidney. After surgery, eight cycles of adjuvant chemotherapy including vincristine, doxorubicin (Adriamycin®), cyclophosphamide, ifosfamide, and etoposide were given. No evidence of recurrence has been observed 13 months from diagnosis. Conclusion This was a rare Ewing sarcoma family tumor in the kidney of a young female with no remarkable family medical history.
- Published
- 2022
- Full Text
- View/download PDF
15. Incidence and risk factors for second malignancies among patients with myeloproliferative neoplasms.
- Author
-
Zhang, Yuhui, Han, Yingdi, Teng, Guangshuai, Du, Chenxiao, Gao, Shan, Yuan, Weiping, Zhang, Lei, and Bai, Jie
- Subjects
- *
MYELOPROLIFERATIVE neoplasms , *SURVIVAL analysis (Biometry) , *OVERALL survival , *SURVIVAL rate , *CHINESE people , *MYELOFIBROSIS - Abstract
Objective: The clinical characteristics and survival of patients with myeloproliferative neoplasms (MPNs) with secondary cancer were analyzed to explore the possible risk factors for secondary cancer in MPN patients. Methods: The clinical characteristics of 1060 Chinese patients with MPN were retrospectively analyzed. The Kaplan–Meier method was used to analyze the survival. The Cox multivariate regression model was used to analyze the risk factors for developing secondary cancer in patients with MPNs. Results: The 1060 patients with MPN had a median follow‐up of 10 years (range 1–50) and a median age of 55 years (range 21–86), and 497 (45.2%) were male. The proportion of PV, ET, and PMF was 52.2%, 33.5%, and 14.3%, respectively. About 28.1% (298/1060) of 1060 MPN patients died. The median survival times of the PV, ET, and PMF groups were 20, 24, and 12 years, respectively (p < 0.0001). In age‐ and sex‐matched healthy Chinese patients, the standardized incidence ratio (SIR) value of developing secondary cancer in MPN patients was 6.41 (95% CI: 4.90–9.48). The median survival time was 14 years in the MPN with secondary cancer group. The Cox multivariate analysis showed that age ≥ 65 years (p < 0.0001, HR = 5.027, 95% CI [2.823, 8.952]), MF‐1 (p = 0.001, HR = 2.887, 95% CI [1.503, 5.545]) were risk factors for developing secondary cancer. Conclusions: The survival of MPN patients with secondary cancer was significantly worse than that of patients without secondary cancer. Compared with normal subjects, MPN patients had a 6.41‐fold increased risk of developing secondary cancer, and age ≥ 65 years and MF‐1 were risk factors for developing secondary cancer in MPN patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Risk of Secondary Cancer after Adjuvant Tamoxifen Treatment for Ductal Carcinoma In Situ: A Nationwide Cohort Study in South Korea.
- Author
-
Kim, Dooreh, Oh, Jooyoung, Seok, Jeong-Ho, Lee, Hye Sun, Jeon, Soyoung, and Yoon, Chang Ik
- Subjects
- *
DUCTAL carcinoma , *TAMOXIFEN , *DISEASE risk factors , *PROPENSITY score matching , *CARCINOMA in situ - Abstract
Endocrine therapy is the mainstay treatment for hormone receptor-positive ductal carcinoma in situ. The aim of this study was to examine the long-term secondary malignancy risk of tamoxifen therapy. The data of patients diagnosed with breast cancer between January 2007 and December 2015 were retrieved from the database of the Health Insurance Review and Assessment Service of South Korea. The International Classification of Diseases, 10th revision, was used to track all-site cancers. Age at the time of surgery, chronic disease status, and type of surgery were considered covariates in the propensity score matching analysis. The median follow-up duration was 89 months. Forty-one patients in the tamoxifen group and nine in the control group developed endometrial cancer. The Cox regression hazard ratio model showed that tamoxifen therapy was the only significant predictor of the development of endometrial cancer (hazard ratio, 2.791; 95% confidence interval, 1.355–5.747; p = 0.0054). No other type of cancer was associated with long-term tamoxifen use. In consonance with the established knowledge, the real-world data in this study demonstrated that tamoxifen therapy is related to an increased incidence of endometrial cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. Estimation of the risk of secondary cancer in rectum and bladder after radiation therapy for prostate cancer using a feasibility dose–volume histogram
- Author
-
Takahiro Aoyama, Hidetoshi Shimizu, Yutaro Koide, Tomoki Kitagawa, Hiroyuki Tachibana, Kojiro Suzuki, and Takeshi Kodaira
- Subjects
Secondary cancer ,Full mathematical model ,F-value ,Excess absolute risk ,Prostate ,Radiotherapy ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
We investigated the risk of secondary cancers in rectum and bladder for prostate cancer radiotherapy using a feasibility assessment tool. We calculated the risk of secondary cancer by generating a dose-volume histogram based on an ideal dose falloff function (f-value). This study found a smaller f-value was associated with a lower secondary cancer risk in the rectum but a higher risk in the bladder. The study suggests setting the f-value at 0-0.1 as the optimization goal for the rectum and 0.4 for the bladder is reasonable and feasible for reducing the risk of secondary cancer and other adverse events.
- Published
- 2023
- Full Text
- View/download PDF
18. Detection of secondary upper gastrointestinal tract cancer during follow‐up esophagogastroduodenoscopy after gastrectomy for gastric cancer
- Author
-
Kosuke Nakane, Keiichi Fujiya, Masanori Terashima, Takanori Kawabata, Yosuke Matsumoto, Satoshi Kamiya, Makoto Hikage, Yutaka Tanizawa, Hiroyuki Ono, and Etsuro Bando
- Subjects
Fine and Gray model ,follow‐up EGD ,gastrectomy ,remnant gastric cancer ,secondary cancer ,Surgery ,RD1-811 ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Abstract Aim Esophagogastroduodenoscopy (EGD) may contribute to early detection of secondary cancer in the upper gastrointestinal tract although the clinical relevance of follow‐up after gastrectomy remains unclear. This study aimed to elucidate the effectiveness of follow‐up EGD by investigating the incidence of secondary cancer in any part of the upper gastrointestinal tract. Methods Data from 1438 patients who underwent curative partial gastrectomy for primary gastric cancer between 2008 and 2014 and follow‐up EGD at least once during a 5‐year follow‐up period were retrospectively reviewed. Incidence rates of remnant gastric cancer, laryngeal cancer, and esophageal cancer detected after follow‐up EGD were determined, and risk factors for secondary cancers were examined. The characteristics of clinicopathological diagnoses of secondary cancers were reviewed and compared according to the frequency of follow‐up EGD. Results The average annual frequency of EGD was 0.7, while the 5‐year cumulative incidence rates of remnant gastric cancer and secondary laryngeal and esophageal cancers were 2.9% and 1.3%, respectively. Risk factors for remnant gastric cancer included heavy smoking, proximal gastrectomy, and tumor size ≥ 30 mm. All secondary cancers were resectable upon diagnosis, with endoscopically resectable cancer accounting for 81.0% of cases. Our results found a significantly higher proportion of endoscopically resectable cancers during regular follow‐up than during infrequent follow‐up. Conclusions Follow‐up EGD can be a useful modality for detecting secondary upper gastrointestinal tract cancer, likely leading to curative treatment for secondary cancer. Focusing on patients presenting with risk factors may increase the value of follow‐up EGD after gastrectomy.
- Published
- 2022
- Full Text
- View/download PDF
19. 小脳髄芽腫治療後に発生した膠芽腫の 分子病理学的解析の導入.
- Author
-
松田章秀, 大江直行, 大久保貴史, 小木曾衛, 今井直哉, 酒々井夏子, 宮崎龍彦, and 岩間 亨
- Abstract
The number of long-term survivors of pediatric medulloblastoma has been increasing due to improved treatment options. However, secondary cancer can be an issue for long-term survivors. Of the 27 patients with cerebellar medulloblastoma treated at our institution, two developed cerebellar glioblastomas after the initial treatment at five years and 11 months and 22 years and eight months, respectively. These two cerebellar glioblastomas were clinically diagnosed as radiation-induced secondary cancer. Both of the two cases we clinically diagnosed as radiation-induced glioblastoma had negative IDH-1, EGFR expression and positive p53 expression in immunohistochemistry, and the molecular evaluation was consistent with radiation-induced secondary cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2023
20. Three-dimensional conformal radiotherapy (3D-CRT) vs. volumetric modulated arc therapy (VMAT) in deep inspiration breath-hold (DIBH) technique in left-sided breast cancer patients—comparative analysis of dose distribution and estimation of projected secondary cancer risk
- Author
-
Racka, Iga, Majewska, Karolina, and Winiecki, Janusz
- Abstract
Purpose: The purpose of this study was to compare two techniques of irradiation of left-sided breast cancer patients who underwent breast-conserving surgery, three-dimensional conformal radiotherapy technique (3D-CRT) and volumetric modulated arc therapy (VMAT), in terms of dose distribution in the planning target volume (PTV) and organs at risk (OARs). The second aim of the study was estimation of the projected risk of radiation-induced secondary cancer for both radiotherapy techniques. Materials and methods: For 25 patients who underwent CT simulation in deep inspiration breath-hold (DIBH), three treatment plans were generated: one using a three-dimensional conformal radiotherapy technique and two using volumetric modulated arc therapy. First VMAT-DIBH geometry consisted of three partial arcs (ARC-DIBH 3A) and second consisted of four partial arcs (ARC-DIBH 4A). Cumulative dose–volume histograms (DVHs) were used to compare dose distributions within the PTV and OARs (heart, left anterior descending coronary artery [LAD], ipsilateral and contralateral lung [IL, CL], and contralateral breast [CB]). Normal tissue complication probabilities (NTCPs) and organ equivalent doses (OEDs) were calculated using the differential DVHs. Excess absolute risks (EARs) for second cancers were estimated using Schneider's full mechanistic dose–response model. Results: All plans fulfilled the criterium for PTV V95% ≥ 95%. The PTV coverage, homogeneity, and conformity indices were significantly better for VMAT-DIBH. VMAT showed a significantly increased mean dose and V5Gy for all OARs, but reduced LAD D
max by 15 Gy. For IL, CL, and CB, the 3D-CRT DIBH method achieved the lowest values of EAR: 28.38 per 10,000 PYs, 2.55 per 10,000 PYs, and 4.48 per 10,000 PYs (p < 0.001), compared to 40.29 per 10,000 PYs, 15.62 per 10,000 PYs, and 23.44 per 10,000 PYs for ARC-DIBH 3A plans and 41.12 per 10,000 PYs, 15.59 per 10,000 PYs, and 22.73 per 10,000 PYs for ARC-DIBH 4A plans. Both techniques provided negligibly low NTCPs for all OARs. Conclusion: The study shows that VMAT-DIBH provides better OAR sparing against high doses. However, the large low-dose-bath (≤ 5 Gy) is still a concern due to the fact that a larger volume of normal tissues exposed to lower doses may increase a radiation-induced risk of secondary cancer. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
21. Out-of-field effects: lessons learned from partial body exposure.
- Author
-
Pazzaglia, S., Eidemüller, M., Lumniczky, K., Mancuso, M., Ramadan, R., Stolarczyk, L., and Moertl, S.
- Abstract
Partial body exposure and inhomogeneous dose delivery are features of the majority of medical and occupational exposure situations. However, mounting evidence indicates that the effects of partial body exposure are not limited to the irradiated area but also have systemic effects that are propagated outside the irradiated field. It was the aim of the "Partial body exposure" session within the MELODI workshop 2020 to discuss recent developments and insights into this field by covering clinical, epidemiological, dosimetric as well as mechanistic aspects. Especially the impact of out-of-field effects on dysfunctions of immune cells, cardiovascular diseases and effects on the brain were debated. The presentations at the workshop acknowledged the relevance of out-of-field effects as components of the cellular and organismal radiation response. Furthermore, their importance for the understanding of radiation-induced pathologies, for the discovery of early disease biomarkers and for the identification of high-risk organs after inhomogeneous exposure was emphasized. With the rapid advancement of clinical treatment modalities, including new dose rates and distributions a better understanding of individual health risk is urgently needed. To achieve this, a deeper mechanistic understanding of out-of-field effects in close connection to improved modelling was suggested as priorities for future research. This will support the amelioration of risk models and the personalization of risk assessments for cancer and non-cancer effects after partial body irradiation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. Radiation increases COL1A1, COL3A1, and COL1A2 expression in breast cancer
- Author
-
Yao Guorong, Zhao Kaiyue, Bao Kaikai, and Li Jing
- Subjects
radiotherapy ,secondary cancer ,breast cancer ,type i collagen ,type iii collagen ,Medicine - Abstract
Radiotherapy-associated secondary cancer is an important issue for the treatment of breast cancer (BCa). This study aimed to investigate the molecular mechanism and genetic risk factors for radiation-associated secondary diseases in BCa.
- Published
- 2022
- Full Text
- View/download PDF
23. Survivorship Follow-Up: Update About Evidence-Based Screening for Secondary Cancers
- Author
-
Demoor-Goldschmidt, Charlotte, de Vathaire, Florent, and Rauh, Stefan, editor
- Published
- 2021
- Full Text
- View/download PDF
24. A simple analytical model for a fast 3D assessment of peripheral photon dose during coplanar isocentric photon radiotherapy
- Author
-
Beatriz Sánchez-Nieto, Ignacio N. López-Martínez, José Luis Rodríguez-Mongua, and Ignacio Espinoza
- Subjects
radiotherapy ,photon peripheral dose ,photon out-of-field dose ,secondary cancer ,stochastic radiation risk ,Monte Carlo ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Considering that cancer survival rates have been growing and that nearly two-thirds of those survivors were exposed to clinical radiation during its treatment, the study of long-term radiation effects, especially secondary cancer induction, has become increasingly important. To correctly assess this risk, knowing the dose to out-of-field organs is essential. As it has been reported, commercial treatment planning systems do not accurately calculate the dose far away from the border of the field; analytical dose estimation models may help this purpose. In this work, the development and validation of a new three-dimensional (3D) analytical model to assess the photon peripheral dose during radiotherapy is presented. It needs only two treatment-specific input parameter values, plus information about the linac-specific leakage, when available. It is easy to use and generates 3D whole-body dose distributions and, particularly, the dose to out-of-field organs (as dose–volume histograms) outside the 5% isodose for any isocentric treatment using coplanar beams [including intensity modulated radiotherapy and volumetric modulated arc therapy (VMAT)]. The model was configured with the corresponding Monte Carlo simulation of the peripheral absorbed dose for a 6 MV abdomen treatment on the International Comission on Radiological Protection (ICRP) 110 computational phantom. It was then validated with experimental measurements using thermoluminescent dosimeters in the male ATOM anthropomorphic phantom irradiated with a VMAT treatment for prostate cancer. Additionally, its performance was challenged by applying it to a lung radiotherapy treatment very different from the one used for training. The model agreed well with measurements and simulated dose values. A graphical user interface was developed as a first step to making this work more approachable to a daily clinical application.
- Published
- 2022
- Full Text
- View/download PDF
25. Detection of secondary upper gastrointestinal tract cancer during follow‐up esophagogastroduodenoscopy after gastrectomy for gastric cancer.
- Author
-
Nakane, Kosuke, Fujiya, Keiichi, Terashima, Masanori, Kawabata, Takanori, Matsumoto, Yosuke, Kamiya, Satoshi, Hikage, Makoto, Tanizawa, Yutaka, Ono, Hiroyuki, and Bando, Etsuro
- Subjects
GASTROINTESTINAL cancer ,STOMACH cancer ,ESOPHAGEAL cancer ,GASTROINTESTINAL system ,GASTRECTOMY ,DIGESTIVE system endoscopic surgery - Abstract
Aim: Esophagogastroduodenoscopy (EGD) may contribute to early detection of secondary cancer in the upper gastrointestinal tract although the clinical relevance of follow‐up after gastrectomy remains unclear. This study aimed to elucidate the effectiveness of follow‐up EGD by investigating the incidence of secondary cancer in any part of the upper gastrointestinal tract. Methods: Data from 1438 patients who underwent curative partial gastrectomy for primary gastric cancer between 2008 and 2014 and follow‐up EGD at least once during a 5‐year follow‐up period were retrospectively reviewed. Incidence rates of remnant gastric cancer, laryngeal cancer, and esophageal cancer detected after follow‐up EGD were determined, and risk factors for secondary cancers were examined. The characteristics of clinicopathological diagnoses of secondary cancers were reviewed and compared according to the frequency of follow‐up EGD. Results: The average annual frequency of EGD was 0.7, while the 5‐year cumulative incidence rates of remnant gastric cancer and secondary laryngeal and esophageal cancers were 2.9% and 1.3%, respectively. Risk factors for remnant gastric cancer included heavy smoking, proximal gastrectomy, and tumor size ≥ 30 mm. All secondary cancers were resectable upon diagnosis, with endoscopically resectable cancer accounting for 81.0% of cases. Our results found a significantly higher proportion of endoscopically resectable cancers during regular follow‐up than during infrequent follow‐up. Conclusions: Follow‐up EGD can be a useful modality for detecting secondary upper gastrointestinal tract cancer, likely leading to curative treatment for secondary cancer. Focusing on patients presenting with risk factors may increase the value of follow‐up EGD after gastrectomy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. Proton beam therapy for a giant hepatic hemangioma: A case report and literature review
- Author
-
Shosei Shimizu, Masashi Mizumoto, Toshiyuki Okumura, Yinuo Li, Keiichirou Baba, Motohiro Murakami, Toshiki Ishida, Masatoshi Nakamura, Yuichi Hiroshima, Takashi Iizumi, Takashi Saito, Haruko Numajiri, Kei Nakai, Masaharu Hata, and Hideyuki Sakurai
- Subjects
Radiotherapy ,Proton beam therapy ,Hemangioma ,Liver ,Secondary cancer ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background: Hepatic hemangiomas are benign tumors with a favorable prognosis, but giant hepatic hemangiomas can cause abdominal symptoms and are indicated for treatment. Most cases are treated with surgery, but radiotherapy has also been used. However, to date, there have been no reports of proton beam therapy for a hepatic hemangioma. Case presentation: A 46-year-old woman had a tumor of 80 × 80 mm in the left medial lobe of the liver, which was diagnosed as a giant hemangioma based on the contrast pattern. Therapy was required for a giant hepatic hemangioma with symptoms, but the patient refused blood transfusion due to religious reasons, which made surgical resection difficult. Therefore, she was referred to our hospital for proton beam therapy. At her first visit, liver function was Child-Pugh A (5 points) and there was no elevation of tumor markers. Proton beam therapy of 28.6 Gy (RBE) given in 13 fractions was performed without interruption. The only observed acute radiation toxicity was Grade 1 dermatitis. One year after proton beam therapy, the hemangioma had significantly decreased, and a complete response has been maintained for 15 years based on ultrasound and MRI. Conclusion: This case is the first reported use of proton beam therapy for a hepatic hemangioma. The outcome suggests that this treatment may be effective for a giant liver hemangioma.
- Published
- 2021
- Full Text
- View/download PDF
27. Risk of Secondary Cancer after Adjuvant Tamoxifen Treatment for Ductal Carcinoma In Situ: A Nationwide Cohort Study in South Korea
- Author
-
Dooreh Kim, Jooyoung Oh, Jeong-Ho Seok, Hye Sun Lee, Soyoung Jeon, and Chang Ik Yoon
- Subjects
secondary cancer ,tamoxifen ,endocrine therapy ,ductal carcinoma in situ ,DCIS ,Medicine (General) ,R5-920 - Abstract
Endocrine therapy is the mainstay treatment for hormone receptor-positive ductal carcinoma in situ. The aim of this study was to examine the long-term secondary malignancy risk of tamoxifen therapy. The data of patients diagnosed with breast cancer between January 2007 and December 2015 were retrieved from the database of the Health Insurance Review and Assessment Service of South Korea. The International Classification of Diseases, 10th revision, was used to track all-site cancers. Age at the time of surgery, chronic disease status, and type of surgery were considered covariates in the propensity score matching analysis. The median follow-up duration was 89 months. Forty-one patients in the tamoxifen group and nine in the control group developed endometrial cancer. The Cox regression hazard ratio model showed that tamoxifen therapy was the only significant predictor of the development of endometrial cancer (hazard ratio, 2.791; 95% confidence interval, 1.355–5.747; p = 0.0054). No other type of cancer was associated with long-term tamoxifen use. In consonance with the established knowledge, the real-world data in this study demonstrated that tamoxifen therapy is related to an increased incidence of endometrial cancer.
- Published
- 2023
- Full Text
- View/download PDF
28. Incidence rate and factors associated with the development of secondary cancers after radioiodine therapy in differentiated thyroid cancer: a multicenter retrospective study.
- Author
-
Hong, Chae Moon, Shin, Ji-Yeon, Kim, Byeong Il, Song, Ho-Chun, Yoon, Joon-Kee, Won, Kyoung Sook, Kim, Seong-Min, Cho, Ihn Ho, Jeong, Shin Young, Lee, Sang-Woo, and Lee, Jaetae
- Subjects
- *
THYROIDECTOMY , *THYROID gland tumors , *MULTIVARIATE analysis , *DISEASE incidence , *RETROSPECTIVE studies , *TERTIARY care , *IODINE radioisotopes , *RADIATION doses , *RADIATION carcinogenesis , *PROPORTIONAL hazards models - Abstract
Purpose: The objective of this study was to estimate the incidence of secondary cancers and the factors associated with their development among patients who underwent radioiodine therapy (RIT) with differentiated thyroid cancer. Methods: We retrospectively collected medical records for patients who underwent first RIT between January 1, 2000, and December 31, 2005, from seven tertiary hospitals in South Korea after total thyroidectomy for differentiated thyroid cancer. Cancer incidence and calculated standardized rate ratio were compared with Korean cancer incidence data. The association between the development of secondary cancers and various parameters was analyzed by Cox-proportional hazard regression. Results: A total of 3106 patients were included in this study. Mean age at the time of diagnosis of thyroid cancer was 45.7 ± 13.3 years old, and 2669 (85.9%) patients were female. The follow-up period was 11.9 ± 4.6 (range, 1.2–19.6) years. A total of 183 secondary cancers, which included 162 solid and 21 hematologic cancers, occurred in 173 patients (5.6%). There was no significant difference between solid cancer incidence in our study population who underwent RIT and the overall Korean population, but the incidence of hematologic cancers and total cancer in our study was significantly higher compared with that of the Korean population. A multivariate analysis identified independent prognostic factors for the development of secondary cancer including age at 1st RIT, male, and total cumulative dose over 200 mCi. Conclusion: We need to assess the risk benefit for patients who receive over 200 mCi of a total cumulative dose. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. مروري بر خطر سرطانهاي ثانویه در پرتودرمانی سرطان پروستات: یک مقاله مروري.
- Author
-
سید حمید ذوالجلا, رضا لاريپور, ابراهیم حضرتی, حامد باقري, نازیلا عیوضزاده, حمید رضا باغانی, and د پروانه اول
- Abstract
Prostate cancer is the most common and second leading cause of death among men in the world. Nowadays, radiotherapy has been known as one of the most affecting methods for prostate cancer treatment. Nevertheless, radiotherapy is accompanied by the concern of developing secondary cancers by the scattered radiation to the neighbor organs at risk. Several studies have shown that secondary cancers after the radiotherapy of prostate cancer treatment, occur in tissues such as the bladder and rectum which have been exposed to direct or indirect radiations. Therefore, this review study aimed to evaluate the influencing factors for developing secondary cancers after the radiotherapy of prostate cancer. To access the previously validated published studies, Persian and English keywords such as prostate cancer, secondary cancers, radiotherapy and organs at risk have been searched in ISID, Google Scholar, Science Direct, PubMed, and World Health Organization, between 1997 and 2021. Totally 246 pieces of literature have been selected which finally, by ignoring the similar and overlapping studies, only 40 studies were reviewed. In the present study, the most affecting factors for developing secondary malignancies including the anatomical status changes, dose variations, smoking and the impact of the various treatment techniques, have been studied. The results of the reviewed studies showed a reduction of secondary cancer risks with performing the modern modalities such as proton therapy to treat prostate cancer. Moreover, organ movements and anatomical status changes which vary from one patient to others, have been reported to make a significant difference in the relative risk of secondary cancers. It has been shown that smoking may increase the risk of secondary cancers after the radiotherapy of prostate cancer, so radiotherapy and smoking may cause genetic mutations. Despite the advantages of radiotherapy for prostate cancer treatment, developing secondary cancers after the radiotherapy should not be ignored. Assessments of the affecting factors for secondary cancers after the radiotherapy of prostate cancer require social and comprehensive studies which can result in an accurate modality with fewer side effects. [ABSTRACT FROM AUTHOR]
- Published
- 2022
30. The impact of modern radiotherapy on long-term cardiac sequelae in breast cancer survivor: a focus on deep inspiration breath-hold (DIBH) technique.
- Author
-
Salvestrini, V., Iorio, G. C., Borghetti, P., De Felice, F., Greco, C., Nardone, V., Fiorentino, A., Gregucci, F., and Desideri, I.
- Subjects
- *
BREAST cancer , *CANCER survivors , *RADIOTHERAPY complications , *CARDIOTOXICITY , *LONGEVITY - Abstract
Introduction: One of the most feared side effects of radiotherapy (RT) in the setting of breast cancer (BC) patients is cardiac toxicity. This side effect can jeopardize the quality of life (QoL) of long-term survivors. The impact of modern techniques of RT such as deep inspiration breath hold (DIBH) have dramatically changed this setting. We report and discuss the results of the literature overview of this paper. Materials and methods: Literature references were obtained with a PubMed query, hand searching, and clinicaltrials.gov. Results: We reported and discussed the toxicity of RT and the improvements due to the modern techniques in the setting of BC patients. Conclusions: BC patients often have a long life expectancy, thus the RT should aim at limiting toxicities and at the same time maintaining the same high cure rates. Further studies are needed to evaluate the risk–benefit ratio to identify patients at higher risk and to tailor the treatment choices. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
31. Coexistence of Thymus and Colon Adenocarcinoma: A Case Report
- Author
-
Muhammed Selim Bodur, Mustafa Tercan, Mümtaz Erakin, Seda Arzuman Baştürk, Ismail Zihni, İsa Sözen, Girayhan Çelik, Mehmet Zafer Sabuncuoglu, and Recep Çetin
- Subjects
colon cancer ,secondary cancer ,thymoma ,Medicine - Abstract
Thymoma is a very rare tumor with a rate of 1.7 per million. Thymoma often occurs between the ages of 35-70. Thymoma is frequently located in the anterior mediastinum. Patients with thymoma often do not cause symptoms clinically. Depending on the localization of the tumor, pain may present with cough, hoarseness, shortness of breath, superior vena cava syndrome and weight loss. The coexistence of nasopharyngeal, breast, colon and hepatocellular cancer can be seen in patients with thymomas. In this article, we present our case with thymoma and colon cancer association with the literature.
- Published
- 2021
- Full Text
- View/download PDF
32. Radiation increases COL1A1, COL3A1, and COL1A2 expression in breast cancer.
- Author
-
Guorong Yao, Kaiyue Zhao, Kaikai Bao, and Jing Li
- Abstract
Background ‒ Radiotherapy-associated secondary cancer is an important issue for the treatment of breast cancer (BCa). This study aimed to investigate the molecular mechanism and genetic risk factors for radiation-associated secondary diseases in BCa. Methods ‒ The differentially expressed genes (DEGs) between preradiation and postradiation BCa samples in the GSE65505 dataset were obtained. The pathways related to the radiation-associated DEGs in the protein–protein interaction (PPI) network modules were identified. miRNAs targeted to the key genes in the PPI network were identified, and their association with BCa prognosis was analyzed. Results ‒ A total of 136 radiation-associated DEGs preradiation and postradiation BCa samples were screened out. The PPI network consisted of a significant module that consisted of 21 upregulated DEGs that were associated with “hsa04512: ECM–receptor interaction,” “hsa04151: PI3K-Akt signaling pathway,” and “hsa04115: p53 signaling pathway.” Sixteen DEGs, including three collagen genes collagen type I alpha 1 chain (COL1A1), COL3A1, and COL1A2, were enriched in 17 radiation-associated pathways. The three genes were upregulated in BCa tissues compared with controls and were also elevated by radiation. They were targeted by hsa-miR-29a/c, and the expression levels of hsa-miR-29a/c were associated with a poor prognosis of BCa. Conclusions ‒ The upregulation of COL1A1, COL3A1, and COL1A2 might be genetic risk factors for radiationassociated secondary diseases in BCa. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
33. A Case Report on Breast Cancer Following Mantle Radiation for Hodgkin Lymphoma: Screening and Management.
- Author
-
Mansour Y and Akinleye A
- Abstract
Hodgkin lymphoma survivors who received mantle radiation are at risk of developing secondary malignant neoplasms. There is no established recommended screening guideline for this population. We discuss the case of a patient with a history of Hodgkin lymphoma status post-mantle field radiation, thyroid cancer status post-thyroidectomy, and now breast cancer following mantle radiation. The risk of adverse effects from mantle field radiation is well documented and includes secondary cancers of the thyroid, breast, lung, and cardiovascular disease. Advances in technology have led to an international paradigm shift in the management of Hodgkin lymphoma to reduce the diameter and dose of radiation based on the patient's anatomy. However, there is no consensus regarding the optimal frequency or modality of breast cancer screening in patients with Hodgkin lymphoma status post-mantle radiation who are now in remission. We discuss screening methods for this population, which has a high risk of developing breast cancer, and emphasize the need for personalized medicine., Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Sovah Health Martinsville IRB issued approval IRB-IORG# 0003200FWA-VA043. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work., (Copyright © 2024, Mansour et al.)
- Published
- 2024
- Full Text
- View/download PDF
34. The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer.
- Author
-
Wenzel, Mike, Nocera, Luigi, Würnschimmel, Christoph, Collà Ruvolo, Claudia, Tian, Zhe, Saad, Fred, Briganti, Alberto, Tilki, Derya, Graefen, Markus, Becker, Andreas, Roos, Frederik C., Chun, Felix K. H., and Karakiewicz, Pierre I.
- Subjects
PROSTATE cancer ,RETRIEVAL practice ,LUNGS ,CANCER diagnosis ,DIAGNOSIS ,ESOPHAGUS - Abstract
Background: This study aims to test the effect of the 10 most common nonurological primary cancers (skin, rectal, colon, lymphoma, leukemia, pancreas, stomach, esophagus, liver, lung) on overall mortality (OM) after secondary prostate cancer (PCa). Material and Methods: Within the Surveillance, Epidemiology, and End Results (SEER) database, patients with 10 most common primary cancers and concomitant secondary PCa (diagnosed 2004–2016) were identified and were matched in 1:4 fashion (age, year at diagnosis, race/ethnicity, treatment type, TNM stage) with primary PCa controls. OM was compared between secondary and primary PCa patients and was stratified according to primary cancer type, as well as according to time interval between primary cancer vs. secondary PCa diagnoses. Results: We identified 24,848 secondary PCa patients (skin, n = 3,871; rectal, n = 798; colon, n = 3,665; lymphoma, n = 2,583; leukemia, n = 1,102; pancreatic, n = 118; stomach, n = 361; esophagus, n = 219; liver, n = 160; lung, n = 1,328) vs. 531,732 primary PCa patients. Secondary PCa characteristics were less favorable than those of primary PCa patients (PSA and grade), and smaller proportions of secondary PCa patients received active treatment. After 1:4 matching, all secondary PCa exhibited worse OM than primary PCa patients. Finally, subgroup analyses showed that the survival disadvantage of secondary PCa patients decreased with longer time interval since primary cancer diagnosis and subsequent secondary PCa. Conclusion: Patients with secondary PCa are diagnosed with less favorable PSA and grade. Even after matching for PCa characteristics, secondary PCa patients still exhibit worse survival. However, the survival disadvantage is attenuated, when secondary PCa diagnosis is made after longer time interval, since primary cancer diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
35. Estimation of Annual Secondary Lung Cancer Deaths Using Various Adjuvant Breast Radiotherapy Techniques for Early-Stage Cancers.
- Author
-
Pignol, Jean-Philippe, Hoekstra, Nienke, Wilke, Derek, Dahn, Hannah, Nolan, Maureen, and Vicini, Frank
- Subjects
LUNG cancer ,BREAST cancer ,HIGH dose rate brachytherapy ,RADIOTHERAPY ,COMPETING risks - Abstract
Purpose: Secondary lung cancer (SLC) can offset the benefit of adjuvant breast radiotherapy (RT), and risks compound sharply after 25 to 30 years. We hypothesized that SLC risk is mainly an issue for early-stage breast cancer, and that lives could be saved using different RT techniques. Patients and Methods: The SEER database was used to extract breast patient age, stage survival, and radiotherapy utilization over time and per stage and to assess the factors associated with increased SLC risk with a multivariable competing risk Cox model. The number of SLC was calculated using the BEIR model modified with patient survival, age, and use of RT from the SEER database. Stage distribution and number of new breast cancer cases were obtained from the NAACCR. Mean lung dose for various irradiation techniques was obtained from measurement or literature. Results: Out of the 765,697 non-metastatic breast cancers in the SEER database from 1988 to 2012, 49.8% received RT. RT significantly increased the SLC risk for longer follow-up (HR=1.58), early stage including DCIS, stage I and IIA (HR = 1.11), and younger age (HR=1.061) (all p<0.001). More advanced stages did not have significantly increased risk. In 2019, 104,743 early-stage breast patients received radiotherapy, and an estimated 3,413 will develop SLC (3.25%) leading to an excess of 2,900 deaths (2.77%). VMAT would reduce this mortality by 9.9%, hypofractionation 26 Gy in five fractions by 38.8%, a prone technique by 70.3%, 3D-CRT APBI by 43.3%, HDR brachytherapy by 71.1%, LDR by 80.7%, and robotic 4π APBI by 85.2%. Conclusions: SLC after breast RT remains a clinically significant issue for early-stage breast cancers. This mortality could be significantly reduced using a prone technique or APBI. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
36. The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer
- Author
-
Mike Wenzel, Luigi Nocera, Christoph Würnschimmel, Claudia Collà Ruvolo, Zhe Tian, Fred Saad, Alberto Briganti, Derya Tilki, Markus Graefen, Andreas Becker, Frederik C. Roos, Felix K. H. Chun, and Pierre I. Karakiewicz
- Subjects
mortality ,primary prostate cancer ,lung cancer ,colon cancer ,secondary cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
BackgroundThis study aims to test the effect of the 10 most common nonurological primary cancers (skin, rectal, colon, lymphoma, leukemia, pancreas, stomach, esophagus, liver, lung) on overall mortality (OM) after secondary prostate cancer (PCa).Material and MethodsWithin the Surveillance, Epidemiology, and End Results (SEER) database, patients with 10 most common primary cancers and concomitant secondary PCa (diagnosed 2004–2016) were identified and were matched in 1:4 fashion (age, year at diagnosis, race/ethnicity, treatment type, TNM stage) with primary PCa controls. OM was compared between secondary and primary PCa patients and was stratified according to primary cancer type, as well as according to time interval between primary cancer vs. secondary PCa diagnoses.ResultsWe identified 24,848 secondary PCa patients (skin, n = 3,871; rectal, n = 798; colon, n = 3,665; lymphoma, n = 2,583; leukemia, n = 1,102; pancreatic, n = 118; stomach, n = 361; esophagus, n = 219; liver, n = 160; lung, n = 1,328) vs. 531,732 primary PCa patients. Secondary PCa characteristics were less favorable than those of primary PCa patients (PSA and grade), and smaller proportions of secondary PCa patients received active treatment. After 1:4 matching, all secondary PCa exhibited worse OM than primary PCa patients. Finally, subgroup analyses showed that the survival disadvantage of secondary PCa patients decreased with longer time interval since primary cancer diagnosis and subsequent secondary PCa.ConclusionPatients with secondary PCa are diagnosed with less favorable PSA and grade. Even after matching for PCa characteristics, secondary PCa patients still exhibit worse survival. However, the survival disadvantage is attenuated, when secondary PCa diagnosis is made after longer time interval, since primary cancer diagnosis.
- Published
- 2021
- Full Text
- View/download PDF
37. Estimation of Annual Secondary Lung Cancer Deaths Using Various Adjuvant Breast Radiotherapy Techniques for Early-Stage Cancers
- Author
-
Jean-Philippe Pignol, Nienke Hoekstra, Derek Wilke, Hannah Dahn, Maureen Nolan, and Frank Vicini
- Subjects
breast radiotherapy ,secondary cancer ,accelerated partial breast irradiation ,brachytherapy ,SBRT ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
PurposeSecondary lung cancer (SLC) can offset the benefit of adjuvant breast radiotherapy (RT), and risks compound sharply after 25 to 30 years. We hypothesized that SLC risk is mainly an issue for early-stage breast cancer, and that lives could be saved using different RT techniques.Patients and MethodsThe SEER database was used to extract breast patient age, stage survival, and radiotherapy utilization over time and per stage and to assess the factors associated with increased SLC risk with a multivariable competing risk Cox model. The number of SLC was calculated using the BEIR model modified with patient survival, age, and use of RT from the SEER database. Stage distribution and number of new breast cancer cases were obtained from the NAACCR. Mean lung dose for various irradiation techniques was obtained from measurement or literature.ResultsOut of the 765,697 non-metastatic breast cancers in the SEER database from 1988 to 2012, 49.8% received RT. RT significantly increased the SLC risk for longer follow-up (HR=1.58), early stage including DCIS, stage I and IIA (HR = 1.11), and younger age (HR=1.061) (all p
- Published
- 2021
- Full Text
- View/download PDF
38. Determination of O6-Methylguanine in dried blood spot of breast cancer patients after cyclophosphamide administration
- Author
-
Yahdiana Harahap, Athalia Theda Tanujaya, Farhan Nurahman, Aurelia Maria Vianney, and Denni Joko Purwanto
- Subjects
Cyclophosphamide ,Dried blood spot (DBS) ,UPLC-MS/MS ,O6-Methylguanine ,Secondary cancer ,Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
Cyclophosphamide is a nitrogen mustard class of drugs that are often used in cancer chemotherapy. However, the use of Cyclophosphamide in high doses over a long period has been shown to increase the risk of developing secondary cancer. This can be indicated by the formation of mutagenic DNA adducts, such as O6-Methylguanine. Therefore, this adduct can be used as a biomarker for secondary cancer in patients receiving Cyclophosphamide. Bio sampling was carried out by using the Dried Blood Spot (DBS) method, followed by DNA extraction by using QIAamp DNA mini kit, and acid hydrolysis to obtain O6-Methylguanine. Analysis of O6-Methylguanine was performed by using the UPLC-MS/MS instrument with the conditions developed by Vianney, Harahap, & Suryadi (2021). Partial validation was carried out before the analysis. The results obtained from the calibration curve, accuracy, and precision validation test met the FDA requirements. The analysis method was then implemented in 16 breast cancer patients who received the Cyclophosphamide regimen. The O6-Methylguanine was successfully detected and quantified in all of the samples in the range of 0.55–6.66 ng/mL. It shows that the O6-Methylguanine accumulation in cancer patients receiving Cyclophosphamide is very likely to occur and the analysis method proposed by Vianney, Harahap, & Suryadi (2021) is potential to be used for Therapeutic Drug Monitoring in this group of patients.
- Published
- 2021
- Full Text
- View/download PDF
39. Radioactive Iodine Treatment for Children and Young Adults with Thyroid Cancer in South Korea: A Population-based Study.
- Author
-
Gi Hyeon Seo, Kyoung Ae Kong, Bom Sahn Kim, Seo Young Kang, Byung Seok Moon, Hai-Jeon Yoon, Hye Ok Kim, Seo, Gi Hyeon, Ae Kong, Kyoung, Kim, Bom Sahn, Seo, Young Kang, Moon, Byung Seok, Yoon, Hai-Jeon, Kim, Hye Ok, Kong, Kyoung Ae, and Kang, Seo Young
- Subjects
YOUNG adults ,IODINE isotopes ,CANCER patients ,THYROID cancer ,THYROID gland ,BREAST ,SALIVARY gland cancer ,HEMATOPOIESIS - Abstract
Purpose: This study investigated radioactive iodine treatment (RAIT) patterns and the secondary cancer incidence among children and young adults receiving RAIT after thyroidectomy for thyroid cancer.Methods: This population-based cohort study used the Health Insurance Review and Assessment database of South Korea to identify a total of 18 617 children and young adults (0-29 years) who underwent thyroidectomy for thyroid cancer between 2008 and 2018. We recorded age at surgery, sex, the interval from surgery to RAIT, the doses of RAI, the number of RAIT sessions, and secondary cancer incidence.Results: A total of 9548 (51.3%) children and young adults underwent 1 or more RAIT sessions. The initial dose of RAIT was 4.35 ± 2.19 GBq. The overall RAIT frequency fell from 60.9% to 38.5%, and the frequency of high-dose RAIT (>3.7 GBq) fell from 64.2% to 36.5% during the observational period. A total of 124 cases of secondary cancer developed during 120 474 person-years of follow-up; 43 (0.5%) in the surgery cohort and 81 (0.8%) in the RAIT cohort. Thus, the RAIT cohort was at an increased risk of secondary cancer (adjusted hazard ratio 1.52 [95% confidence interval 1.03-2.24], P = 0.035).Conclusion: The proportion of children and young adults receiving RAIT, and the RAI dose, fell significantly over the observational period. RAIT was associated with secondary cancers. This is of major concern in the context of child and young adult thyroid cancer survivors. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
40. Mammary Chain Irradiation in Left-Sided Breast Cancer: Can We Reduce the Risk of Secondary Cancer and Ischaemic Heart Disease with Modern Intensity-Modulated Radiotherapy Techniques?
- Author
-
Figlia, Vanessa, Simonetto, Cristoforo, Eidemüller, Markus, Naccarato, Stefania, Sicignano, Gianluisa, De Simone, Antonio, Ruggieri, Ruggero, Mazzola, Rosario, Matuschek, Christiane, Bölke, Edwin, Pazos, Montserrat, Niyazi, Maximilian, Belka, Claus, Alongi, Filippo, and Corradini, Stefanie
- Subjects
RELATIVE medical risk ,MYOCARDIAL ischemia ,LUNG tumors ,DOSE-response relationship (Radiation) ,RADIATION doses ,DESCRIPTIVE statistics ,RADIATION injuries ,RADIOTHERAPY ,BREAST tumors - Abstract
Introduction: The aim of the present study was to estimate the impact of the addition of internal mammary chain (IMC) irradiation in node-positive left-sided breast cancer (BC) patients undergoing regional nodal irradiation (RNI) and comparatively evaluate excess relative and absolute risks of radiation-induced lung cancer/BC and ischaemic heart disease for intensity-modulated radiotherapy (IMRT) versus 3D conformal radiotherapy (3D-CRT). Methods: Four treatment plans were created (3D-CRT and IMRT –/+ IMC) for each of the 10 evaluated patients, and estimates of excess relative risk (ERR) and 10-year excess absolute risk (EAR) were calculated for radiation-induced lung cancer/BC and coronary events using linear, linear-exponential and plateau models. Results: The addition of IMC irradiation to RNI significantly increased the dose exposure of the heart, lung and contralateral breast using both techniques, increasing ERR for secondary lung cancer (58 vs. 44%, p = 0.002), contralateral BC (49 vs. 31%, p = 0.002) and ischaemic heart disease (41 vs. 27%, p = 0.002, IMRT plans). IMRT significantly reduced the mean cardiac dose and mean lung dose as compared to 3D-CRT, decreasing ERR for major coronary events (64% 3D-CRT vs. 41% IMRT, p = 0.002) and ERR for secondary lung cancer (75 vs. 58%, p = 0.004) in IMC irradiation, without a significant impact on secondary contralateral BC risks. Conclusion: Although IMC irradiation has been shown to increase survival rates in node-positive BC patients, it increased dose exposure of organs at risk in left-sided BC, resulting in significantly increased risks for secondary lung cancer/contralateral BC and ischaemic heart disease. In this setting, the adoption of IMRT seems advantageous when compared to 3D-CRT. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
41. Individualized Fraction Regimen of SBRT Patients With Non-Small Cell Lung Cancer Based on Uncomplicated and Cancer-Free Control Probability.
- Author
-
Feng, Ai-Hui, Wang, Hao, Chen, Hua, Gu, Heng-Le, Shao, Yan, Duan, Yan-Hua, Huang, Ying, Fu, Xiao-Long, Zhou, Tao, and Xu, Zhi-Yong
- Subjects
STEREOTACTIC radiotherapy ,NON-small-cell lung carcinoma ,BODY mass index ,RADIATION dosimetry ,LUNG cancer treatment - Abstract
Introduction: Stereotactic body radiotherapy (SBRT) currently adopts non-discriminative prescription regimen. This study attempts to investigate an individualized fraction regimen (IFR) method for SBRT patients with non-small cell lung cancer (NSCLC) based on Uncomplicated and Cancer-free Control Probability (UCFCP). Methods: Twenty patients with NSCLC were retrospectively prescribed with 40 regimens, ranging from 8Gy×5f to 12Gy×5f in step of 0.1 Gy. Taking into consideration of the age and the BMI index of each patient as well, the tumor control probability (TCP), the normal tissue complication probability (NTCP) of the total lung, chest wall and rib, and the secondary cancer probability (SCP) of the total lung were calculated for each plan of the patients. For the 40 regimens, the UCFCP was calculated and the maximum value of UCFCP was the IFR of the specified patient. Besides, IFR of UCP approach which only took account of the TCP and NTCP was also derived and to be compared with the IFR based on the UCFCP method. Results: For all the patients, the UCFCP value showed a bell-shaped trend with the change of prescription dose. Among the 20 patients, the IFRs of 16 patients were different from the original fixed regimen. Of the 16 patients, the IFR of 5 patients exhibited slight changes between UCP and UCFCP methods. Conclusion: The method based on the maximum value of UCFCP function may be helpful to provide IFR for specific SBRT patients with NSCLC, differentiating the patient specific characteristics such as anatomical structures and locations. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
42. Risk of second HPV-associated cancers in men with penile cancer.
- Author
-
Glombik, Dominik, Oxelbark, Åsa, Sundqvist, Pernilla, Carlsson, Jessica, Lambe, Mats, Drevin, Linda, Davidsson, Sabina, and Kirrander, Peter
- Subjects
- *
PENILE tumors , *MEN'S health , *CONFIDENCE intervals , *OROPHARYNGEAL cancer , *CANCER patients , *ANAL tumors , *PAPILLOMAVIRUS diseases , *DESCRIPTIVE statistics , *PROPORTIONAL hazards models , *DISEASE risk factors - Abstract
The aim of this study was to examine the risk of HPV-associated oral cavity, oropharyngeal or anal cancer in men with penile cancer to test the hypothesis of an increased risk to develop a second HPV-associated cancer later in life. We conducted a population-based register study including all men in Sweden diagnosed with penile cancer between 2000 and 2012. For each patient, six men without penile cancer were matched based on age and county of residence. Data were retrieved from Swedish cancer and population registers, to assess the risk of oral cavity, oropharyngeal or anal cancer in patients with penile cancer. Cox proportional hazard models were used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs). Risks in men with penile cancer were also compared with the background Swedish male population by use of standardized incidence ratios. In total, 1634 men with and 9804 without penile cancer were included in the study. Among men with penile cancer, four men were subsequently diagnosed with oral cavity cancer, one with oropharyngeal cancer and one with anal cancer. Corresponding numbers among the penile cancer-free men were ten, two and three, respectively. There was evidence of an increased risks of all three cancers under study with an HR of 2.84 (95% CI 0.89–9.06) for oral cavity cancer, 3.66 (95% CI 0.33–40.39) for oropharyngeal cancer and 2.34 (95% CI 0.24–22.47) for anal cancer. When comparing the incidence of these malignancies between penile cancer patients and the background population, the patterns of association were similar. Our findings indicate that men with penile cancer are at an increased risk of a second HPV-associated cancer of the oral cavity, oropharynx and anal canal. Considering that our study was based on small numbers reflecting the rarity of these cancers, larger studies are needed to confirm our findings. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
43. Estimating the risk of secondary lung cancer from radiotherapy for pediatric Hodgkin’s lymphoma patients using a mechanistic model
- Author
-
Melgarejo, Hidmer Laulate, de Menezes, Artur Ferreira, da Silva, Leonardo Peres, de Araujo Magalhaes, Denise Maria, de Salles Soares, Alessandro Facure Neves, and da Silva, Ademir Xavier
- Published
- 2022
- Full Text
- View/download PDF
44. Evaluation of healthy tissue dose at different regions between volumetric-modulated arc therapy and intensity-modulated radiation therapy plans in the treatment of various cancers
- Author
-
Jayapalan Krishnan, Suresh Rao, Sanath Hegde, and Jayarama Shetty
- Subjects
Healthy tissue ,intensity-modulated radiation therapy ,secondary cancer ,target volume ,volumetric-modulated arc therapy ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Background: Radiotherapy plays an important role in the management of cancer. Although the improved technologies increase therapeutic index, different delivery techniques deliver different dose pattern to the healthy tissue within and outside treatment volume. Objective: The objective of this study was to evaluate the low, intermediate, and high dose to healthy tissue within and outside the treatment volume and to find the relation between tumor volume and various doses received healthy tissue volume. Materials and Methods: A total of 150 patients were included. For all patients, planning computed tomography images were acquired. Tumors, critical structures, and healthy tissue volumes at different regions were delineated. Two sets of plans, one with volumetric-modulated arc therapy and another with intensity-modulated radiation therapy (IMRT) were created, optimized for 6 MV photons and dose was calculated. Dosimetry results for tumor, organs at risks (OARs), and healthy tissue from both the techniques were evaluated and compared. Results: Tumor coverage and dose to OARs was significantly better with volumetric-modulated arc therapy (VMAT). Volume of healthy tissue received high-dose within the treatment volume as well as volume of healthy tissue received low and intermediate-dose out of treatment volume were significantly (P < 0.002) lesser with VMAT. Besides, the results showed that as the tumor volume increased, the various dose received healthy tissue volume also increased. Conclusions: VMAT plan can reduce the risk of secondary malignancy while treating different sites of cancer. VMAT is the most appropriate technique than IMRT, especially in the treatment of large tumor volume. Special attention has to be given, especially while treating women and children.
- Published
- 2019
- Full Text
- View/download PDF
45. Radiation-induced Non-targeted Effect and Carcinogenesis; Implications in Clinical Radiotherapy
- Author
-
R Yahyapour, A Salajegheh, A Safari, P Amini, A Rezaeyan, A Amraee, and M Najafi
- Subjects
Radiation ,Bystander effect ,Carcinogenesis ,Non-targeted effect ,Secondary cancer ,Genomic instability ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Bystander or non-targeted effect is known to be an interesting phenomenon in radiobiology. The genetic consequences of bystander effect on non-irradiated cells have shown that this phenomenon can be considered as one of the most important factors involved in secondary cancer after exposure to ionizing radiation. Every year, millions of people around the world undergo radiotherapy in order to cure different types of cancers. The most crucial aim of radiotherapy is to improve treatment efficiency by reducing early and late effects of exposure to clinical doses of radiation. Secondary cancer induction resulted from exposure to high doses of radiation during treatment can reduce the effectiveness of this modality for cancer treatment. The perception of carcinogenesis risk of bystander effects and factors involved in this phenomenon might help reduce secondary cancer incidence years after radiotherapy. Different modalities such as radiation LET, dose and dose rate, fractionation, types of tissue, gender of patients, etc. may be involved in carcinogenesis risk of bystander effects. Therefore, selecting an appropriate treatment modality may improve cost-effectiveness of radiation therapy as well as the quality of life in survived patients. In this review, we first focus on the carcinogenesis evidence of non-targeted effects in radiotherapy and then review physical and biological factors that may influence the risk of secondary cancer induced by this phenomenon.
- Published
- 2018
46. Skin changes in hairy cell leukemia.
- Author
-
Robak, Ewa, Jesionek-Kupnicka, Dorota, and Robak, Tadeusz
- Subjects
- *
LEUKEMIA , *LEUKOCYTOCLASTIC vasculitis , *DRUG side effects , *SYMPTOMS , *AUTOIMMUNITY , *DIAGNOSIS - Abstract
Skin lesions have been reported in about 10–12% of hairy cell leukemia (HCL) patients. Most are etiologically related to autoimmune or infectious processes, although secondary cutaneous neoplasms and drug-induced lesions are also reported. However, leukemia cutis with the direct infiltration of the skin by leukemic cells is extremely rare in HCL patients. This paper reviews the epidemiology, pathogenesis, clinical symptoms, diagnosis, and approach to treating skin lesions in HCL. A literature review of the MEDLINE database for articles in English concerning hairy cell leukemia, skin lesions, leukemia cutis, adverse events, infectious, cutaneous, drug reactions, neutrophilic dermatoses, secondary neoplasms, and vasculitis was conducted via PubMed. Publications from January 1980 to September 2020 were scrutinized. Additional relevant publications were obtained by reviewing the references from the chosen articles. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
47. Unraveling trajectories from aplastic anemia to hematologic malignancies: genetic and molecular insights.
- Author
-
Kim N, Choi YJ, Lee ST, Choi JR, Lyu CJ, Shin S, and Cheong JW
- Abstract
Background: Aplastic anemia (AA), characterized by hematopoietic stem cell deficiency, can evolve into different hematologic malignancies. Our understanding of the genetic basis and mechanisms of this progression remains limited., Methods: We retrospectively studied 9 acquired AA patients who later developed hematologic malignancies. Data encompassed clinical, laboratory, karyotype, and next-generation sequencing (NGS) information. We explored chromosomal alterations and mutation profiles to uncover genetic changes underlying the transition., Results: Nine AA patients developed myelodysplastic syndrome (seven patients), acute myeloid leukemia (one patient), or chronic myelomonocytic leukemia (one patient). Among eight patients with karyotype results at secondary malignancy diagnosis, monosomy 7 was detected in three. Trisomy 1, der(1;7), del(6q), trisomy 8, and del(12p) were detected in one patient each. Among three patients with NGS results at secondary malignancy diagnosis, KMT2C mutation was detected in two patients. Acquisition of a PTPN11 mutation was observed in one patient who underwent follow-up NGS testing during progression from chronic myelomonocytic leukemia to acute myeloid leukemia., Conclusion: This study highlights the genetic dynamics in the progression from AA to hematologic malignancy. Monosomy 7's prevalence and the occurrence of PTPN11 mutations suggest predictive and prognostic significance. Clonal evolution underscores the complexity of disease progression., Competing Interests: Authors S-TL and JRC were employed by the company Dxome Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Kim, Choi, Lee, Choi, Lyu, Shin and Cheong.)
- Published
- 2024
- Full Text
- View/download PDF
48. Measurement of Neutron Dose Equivalent within and Outside of a LINAC Treatment Vault Using a Neutron Survey Meter
- Author
-
Duong Thanh Tai, Truong Thi Hong Loan, Abdelmoneim Sulieman, Nissren Tamam, Hiba Omer, and David A. Bradley
- Subjects
neutron dosimetry ,secondary cancer ,linear accelerator ,radiation therapy ,Technology ,Electrical engineering. Electronics. Nuclear engineering ,TK1-9971 - Abstract
This work concerns neutron doses associated with the use of a Siemens Primus M5497 electron accelerator, which is operated in the photon mode at 15 MV. The conditions offer a situation within which a fraction of the bremsstrahlung emission energies exceed the photoneutron threshold. For different field sizes, an investigation has been made of neutron dose equivalent values at various measurement locations, including: (i) At the treatment table, at a source-surface distance of 100 cm; (ii) at the level of the floor directly adjacent to the treatment table; and (iii) in the control room and patient waiting area. The evaluated neutron dose equivalent was found to range from 0.0001 to 8.6 mSv/h, notably with the greatest value at the level of the floor directly adjacent to the treatment couch (8.6 mSv/h) exceeding the greatest value on the treatment table (5.5 mSv/h). Low values ranging from unobservable to between 0.0001 to 0.0002 mSv/h neutron dose were recorded around the control room and patient waiting area. For measurements on the floor, the study showed the dose equivalent to be greatest with the jaws closed. These data, most particularly concerning neutron distribution within the treatment room, are of great importance in making steps towards improving patient safety via the provision of protective measures.
- Published
- 2021
- Full Text
- View/download PDF
49. Re-irradiation using proton therapy for radiation-induced secondary cancer with Li-Fraumeni syndrome: A case report and review of literature.
- Author
-
Iwasaki, Tomoya, Mizumoto, Masashi, Numajiri, Haruko, Oshiro, Yoshiko, Suzuki, Ryoko, Moritani, Kyoko, Eguchi, Mariko, Ishii, Eiichi, and Sakurai, Hideyuki
- Subjects
- *
LI-Fraumeni syndrome , *PROTON therapy , *GRANULOCYTE-colony stimulating factor , *RADIATION injuries , *LITERATURE reviews , *GENETIC disorders , *RADIATION carcinogenesis - Abstract
Li-Fraumeni syndrome (LFS) is a genetic disease that is hypersensitive to radiotherapy. Proton therapy (PT) was strongly recommended for pediatric and radiation-sensitive tumors. However, there is little information on PT for LFS. The patient was a 7-year-old girl with LFS who was diagnosed with radiation-induced right shoulder blade osteosarcoma and left chest wall malignant fibrous histiocytoma. Both tumors were in the area that had previously been irradiated (36–45 Gy by photon radiotherapy). Sixty-six GyE in 30 fractions was planned for both tumors. We set the clinical target to the minimum gross tumor volume. To comprehensively assess any adverse events, PT was conducted under hospital administration. Cisplatin was used as simultaneous combination chemotherapy. Although administration of granulocyte-colony stimulating factor was necessary for myelosuppression by chemotherapy, PT was completed without interruption. Acute radiation toxicity was observed as Grade 1 dermatitis. The dermatitis became exacerbated 2 weeks after PT but subsequently improved with conservation treatment alone. Twenty-three months after PT, magnetic resonance imaging showed an increase in the tumor on the right shoulder. A histological examination was not conducted as the family declined, but secondary cancer was suggested rather than recurrent osteosarcoma, as the tumor developed mainly from the soft tissue. Additional surgical treatment and radiotherapy were not indicated, and the patient died of tumor progression and sepsis caused by myelosuppression 27 months after undergoing PT. Up to 23 months after PT, there were no signs of Grade 2 or more late toxicities. This represents the first reported case of PT for a patient with LF to treat radiation-induced secondary cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
50. Temporal trends of subsequent breast cancer among women with ovarian cancer: a population-based study.
- Author
-
Matsuo, Koji, Mandelbaum, Rachel S., Machida, Hiroko, Yoshihara, Kosuke, Matsuzaki, Shinya, Klar, Maximilian, Muggia, Franco M., Roman, Lynda D., and Wright, Jason D.
- Subjects
- *
BREAST cancer , *OVARIAN cancer , *CANCER diagnosis , *HEREDITARY cancer syndromes - Abstract
Purpose: To examine trends, characteristics and outcomes of women who develop both ovarian and breast cancers.Methods: This is a retrospective study examining the Surveillance, Epidemiology, and End Results Program from 1973 to 2013. Among ovarian cancer (n = 133,149) and breast cancer (n = 1,143,219) cohorts, women with both diagnoses were identified and temporal trends, tumor characteristics and survival were examined.Results: There were 6446 women with both malignancies, representing 4.8% of the ovarian cancer cohort and 0.6% of the breast cancer cohort. Women with ovarian cancer who had secondary breast cancer were younger than those without secondary breast cancer early in the study period (52.3 versus 59.2 in 1973) but older in more recent years (68.5 versus 62.1 in 2013, P < 0.001). The number of breast cancer survivors who developed postcedent ovarian cancer decreased from 1.5 to 0.2% from 1979 to 2008 (relative risk reduction 90.0%, P < 0.05). Similarly, the number of ovarian cancer survivors who developed postcedent breast cancer decreased from 7.2 to 2.0% from 1973 to 2008 (relative risk reduction 72.4%, P < 0.05). Tumor characteristics were more likely to be favorable in women with ovarian cancer who developed postcedent breast cancer but unfavorable in those who had antecedent breast cancer (all, P < 0.05). Women with ovarian cancer who had secondary breast cancer had superior cause-specific survival compared to those who did not develop breast cancer regardless of breast cancer timing (P < 0.05).Conclusion: Our study demonstrated that the demographics of women who develop breast cancer and ovarian cancer have changed over time and diagnosis of secondary breast cancer after ovarian cancer has decreased. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.